Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hemisphere

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    61 result(s) found for: Hemisphere. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2007-000752-14 Sponsor Protocol Number: GRT82 Start Date*: 2011-04-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 Formulation (Intramuscular Route)
    Medical condition: Vaccination of healthy subjects aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion with one dose of the ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000671-15 Sponsor Protocol Number: GRT63 Start Date*: 2006-05-04
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route)
    Medical condition: Vaccination of healthy subjects aged 18 to 60 years (60 subjects) and over the 60 years (60 subjects) with one dose of the new formulation of the influenza vaccine for the 2006-2007 Northern Hemisp...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000943-33 Sponsor Protocol Number: GRT83 Start Date*: 2008-04-23
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation (Intramuscular Route)
    Medical condition: Vaccination of healthy subjects aged 18 to 60 years (i.e. to the day before the 61st birthday) or 61 years or above (from the day of the 61st birthday) on the day of inclusion with one dose of the ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010761-22 Sponsor Protocol Number: 82/09 Start Date*: 2009-04-25
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: ECG changes and C-protein level variations during and after treatment with atorvastatin at different dosages in the secondary prevention of stroke.
    Medical condition: Stroke
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001279-19 Sponsor Protocol Number: SONAS2018 Start Date*: 2019-08-19
    Sponsor Name:BURL Concepts, Inc.
    Full Title: Evaluation of the SONAS® ultrasound device for the assessment of bilateral cerebral perfusion in subjects with acute stroke
    Medical condition: Acute large vessel occlusion (LVO) stroke (NIHSS score: ≥ 10)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000881-12 Sponsor Protocol Number: M13-998 Start Date*: 2013-07-11
    Sponsor Name:Abbott Biologicals B.V
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2013/2014. An Open-Label, Baseline- Controlled Study in Two Age Gro...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005243-25 Sponsor Protocol Number: GID37 Start Date*: 2013-04-16
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route)
    Medical condition: Prophylaxis of influenza (2013-2014 Northern Hemisphere Season)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-009977-85 Sponsor Protocol Number: GID29 Start Date*: 2009-05-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route)
    Medical condition: Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intradermal route
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000629-19 Sponsor Protocol Number: GID47 Start Date*: 2014-08-21
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety assessment of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2014-2015 Formulation (Intradermal Route)
    Medical condition: Prophylaxis of influenza (2014-2015 Northern Hemisphere Season)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001032-57 Sponsor Protocol Number: M13-567 Start Date*: 2012-06-26
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2012/2013. An Open-Label, Baseline- Controlled Study in Two Age ...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000175-27 Sponsor Protocol Number: CSLCT-USF-10-69 Start Date*: 2015-03-23
    Sponsor Name:bioCSL Pty Ltd
    Full Title: A Phase IV, Multicenter, Randomized, Observer-blind, Parallel-arm Study to Evaluate the Safety and Tolerability of CSL’s Trivalent Influenza Virus Vaccine (CSL TIV) in Children 5 to Less Than 9 Yea...
    Medical condition: Influenza, human
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001044-35 Sponsor Protocol Number: GQM00016 Start Date*: 2019-02-08
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine in Children Aged 6 months to 17 Years
    Medical condition: Prophylaxis of influenza (Northern Hemisphere 2017-2018 season) in children aged 6 months to 17 years
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006949-13 Sponsor Protocol Number: BRD/06/162 Start Date*: 2007-10-16
    Sponsor Name:University College London
    Full Title: A multi-centre exploratory study to evaluate the efficacy of the dopamine receptor agonist rotigotine in the treatment of hemispatial neglect and motor deficits following stroke.
    Medical condition: Hemispatial neglect and motor deficits following right-hemisphere stroke.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000755-97 Sponsor Protocol Number: EPFL-CNBI-2017-01 Start Date*: 2017-03-16
    Sponsor Name:Defitech Chair in Brain-Machine Interface, EPFL
    Full Title: Brain-computer interface and neuromuscular stimulation for rehabilitation following chronic stroke
    Medical condition: I61 - Intracerebral haemorrhage I63 - Cerebral infarction Chronic condition (at least 10 months after occurrence of cerebrovascular accident)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2007-001465-14 Sponsor Protocol Number: CSLCT-NHF-06-30 Start Date*: 2007-05-17
    Sponsor Name:CSL Limited
    Full Title: A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira Vaccine in Healthy Adults aged ≥ 18 to < 60 years and in Healthy Older Adults aged ≥ 60 years for the 2007/2008...
    Medical condition: Prophylaxis of Influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000651-14 Sponsor Protocol Number: CSLCT-NHF-04-99 Start Date*: 2005-05-27
    Sponsor Name:CSL Limited
    Full Title: A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Influenza Vaccine, CSL Limited in Healthy 'Adults' aged >18 to <60 years and in Healthy 'Older Adults' aged >60 years fo...
    Medical condition: The vaccine is indicated for the prophylaxis of influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001422-14 Sponsor Protocol Number: CSLCT-NHF-07-49 Start Date*: 2008-04-29
    Sponsor Name:CSL Limited
    Full Title: A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira® vaccine in Healthy ‘Adults’ aged ≥ 18 to < 60 years and in Healthy ‘Older Adults’ aged ≥ 60 years for the 2008...
    Medical condition: Prophylaxis of influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002068-25 Sponsor Protocol Number: CSLCT-NHF-05-13 Start Date*: 2006-05-23
    Sponsor Name:CSL Limited
    Full Title: A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira in Healthy 'Adults' aged >18 to <60 years and in Healthy 'Older Adults' aged >60 years for the 2006/2007 Northern...
    Medical condition: Prophylaxis of influenza
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002680-18 Sponsor Protocol Number: 107975 Start Date*: 2006-08-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, controlled, randomized, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine adjuvanted with AS03 compared to Fluarix™ (GlaxoSm...
    Medical condition: Immunization against influenza in male and female subjects aged 60 years and older.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023105-35 Sponsor Protocol Number: IC/VG/P01-2010 Start Date*: 2010-10-14
    Sponsor Name:Cantacuzino National Institute of Research and Development for Microbiology and Immunology
    Full Title: The Study of the Immunogenity and Reactogenity of Trivalent, Purified, Inactivated Influenza Vaccine for Parenteral Administration in Adults, for the 2010-2011 Season, Produced by Cantacuzino Natio...
    Medical condition: Healthy adult volunteers (2 age-groups: 18-60 years and >60 years old) are vaccinated in order to achieve protection against influenza virus infection with the vaccine containing the influenza viru...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:31:28 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA